Sea Buckthorn Is Not Recommended for Treating Ulcerative Colitis
Sea buckthorn should not be used as a treatment for ulcerative colitis, as it is not included in any established clinical guidelines and lacks high-quality human clinical trial evidence demonstrating efficacy for morbidity, mortality, or quality of life outcomes in UC patients.
Why Sea Buckthorn Is Not Guideline-Recommended
The most recent and authoritative guidelines for UC management—the 2025 British Society of Gastroenterology guidelines 1 and the 2015 Toronto Consensus 2—make no mention of sea buckthorn in any form. These guidelines establish a clear treatment hierarchy:
- First-line therapy: 5-ASA (mesalazine) preparations, either topical (1g daily for proctitis) or oral (2-4.8g daily for more extensive disease) 2, 1
- Second-line therapy: Corticosteroids (prednisolone 40mg daily) for moderate-to-severe disease or 5-ASA failure 1
- Advanced therapy: Biologics, JAK inhibitors, or S1P agonists for steroid-refractory or steroid-dependent disease 1
The Evidence Gap for Sea Buckthorn
While recent preclinical studies show sea buckthorn components may have anti-inflammatory effects in mouse models of colitis 3, 4, 5, 6, 7, these are exclusively animal studies with no human clinical trial data. The research demonstrates:
- Polysaccharides from sea buckthorn pericarp modulate gut microbiota and reduce inflammation in DSS-induced colitis mice 4, 7
- Total flavonoids from sea buckthorn leaves enhance intestinal barrier function in mouse models 3
- Sea buckthorn berry extracts increase beneficial bacteria like Faecalibaculum rodentium and butyrate production in mice 6
- Fermented sea buckthorn milk with probiotics shows anti-inflammatory effects in animal models 5
Critical limitation: None of these formulations have been tested in randomized controlled trials in humans with UC. The leap from mouse models to clinical efficacy is substantial and unproven.
What About Other Dietary Supplements?
A 2026 network meta-analysis of dietary supplements in UC 8 examined 24 RCTs with 1,491 participants but did not include sea buckthorn. The supplements with actual human evidence included probiotics, curcumin, flaxseed extract, and butyrate—but even these showed only modest benefits as adjunctive therapy, not as primary treatment.
Another 2026 review 9 concluded that while curcumin combined with 5-ASA has "the most consistent randomised clinical evidence" for mild-to-moderate UC, most other nutraceuticals remain "preliminary, heterogeneous or of low-to-very-low certainty."
Clinical Bottom Line
Use evidence-based therapies with proven efficacy:
- For mild-to-moderate UC: Start with oral 5-ASA (2-4g daily) ± topical 5-ASA (1g daily) 2, 1
- For inadequate response at 2-4 weeks: Add prednisolone 40mg daily 1
- For steroid failure/dependence: Escalate to advanced therapies (biologics, JAK inhibitors) 1
Do not substitute or delay proven treatments with unvalidated supplements like sea buckthorn. The risk is disease progression, complications (toxic megacolon, perforation, colorectal cancer), and preventable morbidity.
Common Pitfall to Avoid
Patients may seek "natural" alternatives due to concerns about medication side effects. While this is understandable, delaying effective treatment with unproven supplements can lead to irreversible complications. If patients insist on complementary approaches, these should only be considered as adjuncts to—never replacements for—guideline-directed medical therapy, and only after discussing the lack of human evidence and potential for harm through treatment delay.